A Phase 2 Study of Pembrolizumab (MK-3475) Every 6 Weeks (Q6W) in Participants With Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Diffuse large B cell lymphoma; Hodgkin's disease
Focus Therapeutic Use
Acronyms KEYNOTE B68
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

12 Dec 2023 Results assessing Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
10 Nov 2023 Planned End Date changed from 20 Sep 2024 to 31 Dec 2025.
10 Nov 2023 Planned primary completion date changed from 20 Sep 2024 to 20 Jan 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight